Skip to main content

Table 2 Patient characteristics

From: Tight perioperative glucose control is associated with a reduction in renal impairment and renal failure in non-diabetic cardiac surgical patients

 

Control

Insulin

p Value

Period

August to December 2004

June 2005 to June 2006

 

Total (n)

305

745

 

Female

103 (33.8)

265 (35.6)

0.61

Body Mass Index, mean ± SD

26.1 ± 4.0

26.0 ± 4.3

0.98

Insulin-treated diabetics, n (%)

17 (5.6)

33 (4.4)

0.43

Non-Insulin-treated diabetics, n (%)

33 (10.8)

89 (11.9)

0.67

Untreated diabetics with fasting glucose ≥ 125 mg/dL, n (%)

22 (7.2)

40 (5.4)

0.25

Fasting glucose (mg/dL)

106 ± 31

107 ± 26

0.11

Unstable angina, n (%)

4 (1.3)

11 (1.5)

1.0

Congestive heart failure, n (%)

48 (15.8)

128 (17.2)

0.65

LVEF 30% to 50%, n (%)

47 (15.6)

99 (13.3)

0.38

LVEF < 30%, n (%)

23 (7.6)

60 (8.1)

0.89

Recent myocardial infarction, n (%)

9 (3)

18 (2.4)

0.67

COPD, n (%)

32 (10.5)

63 (8.4)

0.29

Peripheral arteriopathy, n (%)

5 (1.6)

16 (2.1)

0.80

Neurologic dysfunction, n (%)

19 (6.3)

37 (4.9)

0.45

Serum creatinine > 2.1 mg/dL, n (%)

6 (1.9)

17 (2.3)

1.0

Endocarditis, n (%)

3 (1.0)

8 (1.1)

1.0

Angiotensin-converting Enzyme Inhibitors

105 (34.4)

296 (39.7)

0.12

EuroSCORE, mean ± SD

4 ± 3

4 ± 3

0.76

Cleveland Clinic Severity Score

2 ± 2

3 ± 2

0.19

  1. Data are presented as mean ± SD or number (%) unless otherwise mentioned.
  2. COPD, chronic obstructive pulmonary disease; EuroSCORE, European System for Cardiac Operative Risk Evaluation; LVEF, left ventricular ejection fraction; SD, standard deviation.